Open the source
Follow a tirzepatide fact back to its source
Want to check a fact? These links open the labels, studies and FDA explanations used in the stories.
If you searched for “tirzepatide BNF,” a quick note: this page doesn’t reproduce a BNF monograph. The labels and access information used here have a U.S. focus. They don’t supply prescribing guidance for another country.
Every external source linked in our stories is listed below. You can follow a phrase in a story straight to the same record. Pick the subject you want to check; there’s no need to read the whole pile.
Start with the exact product
Zepbound (tirzepatide) prescribing information supports the pages on appetite, half life, approved uses and side effects. It includes study results and patient information. It isn’t an approval record for compounded preparations.
Mounjaro (tirzepatide) prescribing information supports the diabetes and heart-risk discussion. It also sets out the thyroid warning and reasons the medicine is ruled out for some people. The shared ingredient doesn’t give both products identical uses.
For a question about a warning, the product name is a useful detail to keep beside your notes. It helps avoid mixing up labels during a conversation with a clinician.
The three research findings
The weight-management trial by Jastreboff and colleagues enrolled adults without diabetes who had obesity, or overweight with a weight-related problem. It supplies the average weight changes on our research page and the study amounts on our dosage page. It reports side effects too.
The diabetes trial by Frias and colleagues measured blood sugar over 40 weeks in adults with type 2 diabetes. Participants and researchers knew which treatment was given. We use it to explain the blood-sugar finding, without ranking medicines for an individual reader.
The continuation trial by Aronne and colleagues was a weight-management study. It compared continuing tirzepatide with switching to placebo for 52 weeks, after adults had completed 36 weeks on tirzepatide with weight loss on average. It supports the discussion of average weight regain after stopping in that group. It doesn’t prescribe a treatment length for everyone.
FDA on compounded medicines
FDA’s compounding questions and answers explains the approval distinction. Its page on compounded-drug risks explains what the agency doesn’t check before these medicines reach the market.
FDA’s GLP-1 compounding policy supplies the shortage-related context. The prescription page links it for that limited purpose. A source can explain a rule or a finding; your own health still needs a conversation with someone able to assess it.